Published in Chem Biol Drug Des on March 01, 2007
Derivatives of aryl amines containing the cytotoxic 1,4-dioxo-2-butenyl pharmacophore. Bioorg Med Chem Lett (2010) 0.75
A safe operating space for humanity. Nature (2009) 22.25
Global desertification: building a science for dryland development. Science (2007) 10.15
Resilience and sustainable development: building adaptive capacity in a world of transformations. Ambio (2002) 5.36
A checklist for ecological management of landscapes for conservation. Ecol Lett (2007) 2.76
Reconnecting to the biosphere. Ambio (2011) 2.43
Ecosystem stewardship: sustainability strategies for a rapidly changing planet. Trends Ecol Evol (2009) 2.39
Clinical relevance of the ESKAPE pathogens. Expert Rev Anti Infect Ther (2013) 2.24
Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities. J Biol Chem (2006) 2.05
Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. Chem Rev (2002) 1.81
Zinc induces structural reorganization of gelatin binding domain from human fibronectin and affects collagen binding. Structure (2010) 1.63
Staphylococcus epidermidis device-related infections: pathogenesis and clinical management. J Pharm Pharmacol (2008) 1.58
An intracellular serpin regulates necrosis by inhibiting the induction and sequelae of lysosomal injury. Cell (2007) 1.56
Coping with uncertainty: a call for a new science-policy forum. Ambio (2003) 1.51
The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev (2005) 1.47
Regulation of collagenase activities of human cathepsins by glycosaminoglycans. J Biol Chem (2003) 1.46
Small molecule affinity fingerprinting. A tool for enzyme family subclassification, target identification, and inhibitor design. Chem Biol (2002) 1.42
Building resilience and adaptation to manage Arctic change. Ambio (2006) 1.40
Proteasome inhibitors in cancer therapy. J Cell Commun Signal (2011) 1.38
Pivotal role of cathepsin K in lung fibrosis. Am J Pathol (2004) 1.35
Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium. Arthritis Rheum (2002) 1.34
The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells. Biochem J (2005) 1.27
Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy. J Pharm Pharmacol (2011) 1.27
Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res (2006) 1.25
Cathepsin V, a novel and potent elastolytic activity expressed in activated macrophages. J Biol Chem (2004) 1.24
Monitoring compartment-specific substrate cleavage by cathepsins B, K, L, and S at physiological pH and redox conditions. BMC Biochem (2009) 1.21
Adaptive management of the Great Barrier Reef and the Grand Canyon world heritage areas. Ambio (2007) 1.21
MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica (2008) 1.20
Inhibitory activity of a heterochromatin-associated serpin (MENT) against papain-like cysteine proteinases affects chromatin structure and blocks cell proliferation. J Biol Chem (2002) 1.17
Biochemical properties and regulation of cathepsin K activity. Biochimie (2007) 1.15
Cathepsin K activity-dependent regulation of osteoclast actin ring formation and bone resorption. J Biol Chem (2008) 1.14
The crystal and molecular structures of a cathepsin K:chondroitin sulfate complex. J Mol Biol (2008) 1.14
Glycosaminoglycan-mediated loss of cathepsin K collagenolytic activity in MPS I contributes to osteoclast and growth plate abnormalities. Am J Pathol (2009) 1.13
Selective inhibition of the collagenolytic activity of human cathepsin K by altering its S2 subsite specificity. Biochemistry (2002) 1.10
Multiscale regime shifts and planetary boundaries. Trends Ecol Evol (2013) 1.08
Antibody-mediated inhibition of cathepsin S blocks colorectal tumor invasion and angiogenesis. Clin Cancer Res (2009) 1.07
Amplification of MMP-2 and MMP-9 production by prostate cancer cell lines via activation of protease-activated receptors. Prostate (2004) 1.07
Mucosal allergic sensitization to cockroach allergens is dependent on proteinase activity and proteinase-activated receptor-2 activation. J Immunol (2011) 1.07
Multihospital outbreak of Clostridium difficile ribotype 027 infection: epidemiology and analysis of control measures. Infect Control Hosp Epidemiol (2011) 1.06
Development of real-time PCR assays for the specific detection of Francisella tularensis ssp. tularensis, holarctica and mediaasiatica. Mol Cell Probes (2009) 1.03
Cathepsin S expression: An independent prognostic factor in glioblastoma tumours--A pilot study. Int J Cancer (2006) 1.02
Antimicrobial activity of short, synthetic cationic lipopeptides. Chem Biol Drug Des (2010) 1.01
Cleavage site specificity of cathepsin K toward cartilage proteoglycans and protease complex formation. Biol Chem (2003) 1.00
NF-kappaB protects from the lysosomal pathway of cell death. EMBO J (2003) 1.00
Comparative analysis of synovial fluid and plasma proteomes in juvenile arthritis--proteomic patterns of joint inflammation in early stage disease. J Proteomics (2009) 0.99
Inhibition of cathepsin K with lysosomotropic macromolecular inhibitors. Biochemistry (2002) 0.99
The potential of antimicrobial peptides as biocides. Int J Mol Sci (2011) 0.99
Effects of cysteine proteases on the structural and mechanical properties of collagen fibers. J Biol Chem (2013) 0.98
The clinical significance of cathepsin S expression in human astrocytomas. Am J Pathol (2003) 0.98
Irreversible inhibition of the bacterial cysteine protease-transpeptidase sortase (SrtA) by substrate-derived affinity labels. Biochem J (2002) 0.97
The serpin SQN-5 is a dual mechanistic-class inhibitor of serine and cysteine proteinases. Biochemistry (2002) 0.97
Evidence that serpin architecture intrinsically supports papain-like cysteine protease inhibition: engineering alpha(1)-antitrypsin to inhibit cathepsin proteases. Biochemistry (2002) 0.96
Novel inhibitors of the Pseudomonas aeruginosa virulence factor LasB: a potential therapeutic approach for the attenuation of virulence mechanisms in pseudomonal infection. Antimicrob Agents Chemother (2011) 0.96
Biomolecular mechanisms of staphylococcal biofilm formation. Future Microbiol (2013) 0.95
Cysteine protease cathepsin F is expressed in human atherosclerotic lesions, is secreted by cultured macrophages, and modifies low density lipoprotein particles in vitro. J Biol Chem (2004) 0.95
Gene delivery using dimethyldidodecylammonium bromide-coated PLGA nanoparticles. Biomaterials (2010) 0.94
Pharmacological inhibition of cathepsin S decreases atherosclerotic lesions in Apoe-/- mice. J Cardiovasc Pharmacol (2010) 0.94
Gentamicin-loaded nanoparticles show improved antimicrobial effects towards Pseudomonas aeruginosa infection. Int J Nanomedicine (2012) 0.93
Eradication of Pseudomonas aeruginosa biofilms by atmospheric pressure non-thermal plasma. PLoS One (2012) 0.93
Antibody conjugates and therapeutic strategies. Mol Interv (2005) 0.93
Cathepsin S from both tumor and tumor-associated cells promote cancer growth and neovascularization. Int J Cancer (2013) 0.93
Classical and neonatal Marfan syndrome mutations in fibrillin-1 cause differential protease susceptibilities and protein function. J Biol Chem (2011) 0.93
Role of cathepsin K in structural changes in brachiocephalic artery during progression of atherosclerosis in apoE-deficient mice. Atherosclerosis (2008) 0.93
SRP-2 is a cross-class inhibitor that participates in postembryonic development of the nematode Caenorhabditis elegans: initial characterization of the clade L serpins. J Biol Chem (2004) 0.92
From sentencing to execution--the processes of apoptosis. J Pharm Pharmacol (2010) 0.92
The amplified mouse squamous cell carcinoma antigen gene locus contains a serpin (Serpinb3b) that inhibits both papain-like cysteine and trypsin-like serine proteinases. Genomics (2004) 0.92
Cholate-containing high-fat diet induces the formation of multinucleated giant cells in atherosclerotic plaques of apolipoprotein E-/- mice. Arterioscler Thromb Vasc Biol (2010) 0.91
The use of lytic bacteriophages in the prevention and eradication of biofilms of Proteus mirabilis and Escherichia coli. FEMS Immunol Med Microbiol (2010) 0.91
The therapeutic potential of the proteasome in leukaemia. Hematol Oncol (2008) 0.91
Skin bradykinin-related peptides (BRPs) and their biosynthetic precursors (kininogens): comparisons between various taxa of Chinese and North American ranid frogs. Peptides (2007) 0.91
Cathepsins F and S block HDL3-induced cholesterol efflux from macrophage foam cells. Biochem Biophys Res Commun (2003) 0.91
Probing cathepsin K activity with a selective substrate spanning its active site. Biochem J (2003) 0.91
ApoE-deficient mice on cholate-containing high-fat diet reveal a pathology similar to lung sarcoidosis. Am J Pathol (2010) 0.90
Antifibrotic effects of curcumin are associated with overexpression of cathepsins K and L in bleomycin treated mice and human fibroblasts. Respir Res (2011) 0.89
The human cysteine protease cathepsin V can compensate for murine cathepsin L in mouse epidermis and hair follicles. Eur J Cell Biol (2004) 0.89
Structure-activity analysis of cathepsin K/chondroitin 4-sulfate interactions. J Biol Chem (2010) 0.89
Proteases implicated in apoptosis: old and new. J Pharm Pharmacol (2010) 0.89
Elements of the granular gland peptidome and transcriptome persist in air-dried skin of the South American orange-legged leaf frog, Phyllomedusa hypocondrialis. Peptides (2006) 0.89
Vascular smooth muscle cells efficiently activate a new proteinase cascade involving plasminogen and fibronectin. J Cell Biochem (2003) 0.89
The S2 subsites of cathepsins K and L and their contribution to collagen degradation. Protein Sci (2007) 0.89
Recombinant cathepsin S propeptide attenuates cell invasion by inhibition of cathepsin L-like proteases in tumor microenvironment. Mol Cancer Ther (2008) 0.89
The effect of cathepsin K deficiency on airway development and TGF-β1 degradation. Respir Res (2011) 0.89
Synergistic phage-antibiotic combinations for the control of Escherichia coli biofilms in vitro. FEMS Immunol Med Microbiol (2012) 0.88
ZapA, a virulence factor in a rat model of Proteus mirabilis-induced acute and chronic prostatitis. Infect Immun (2008) 0.88
Proteasome proteolytic activity in hematopoietic cells from patients with chronic myeloid leukemia and multiple myeloma. Haematologica (2004) 0.88
Regulation of cathepsin K activity by hydrogen peroxide. Biol Chem (2008) 0.88
Comparative substrate specificity analysis of recombinant human cathepsin V and cathepsin L. Arch Biochem Biophys (2004) 0.87
S3 to S3' subsite specificity of recombinant human cathepsin K and development of selective internally quenched fluorescent substrates. Biochem J (2003) 0.87
Electrical methods of controlling bacterial adhesion and biofilm on device surfaces. Expert Rev Med Devices (2013) 0.87
SERPINB11 is a new noninhibitory intracellular serpin. Common single nucleotide polymorphisms in the scaffold impair conformational change. J Biol Chem (2007) 0.87
Kininogen-derived peptides for investigating the putative vasoactive properties of human cathepsins K and L. Eur J Biochem (2003) 0.86
Inhibition of the cysteine proteinases cathepsins K and L by the serpin headpin (SERPINB13): a kinetic analysis. Arch Biochem Biophys (2003) 0.86
Application of atmospheric pressure nonthermal plasma for the in vitro eradication of bacterial biofilms. FEMS Immunol Med Microbiol (2012) 0.86
Proteasome-mediated effects on amyloid precursor protein processing at the gamma-secretase site. Biochem J (2005) 0.85
The role of basic amino acid surface clusters on the collagenase activity of cathepsin K. Biochemistry (2013) 0.85
Strategies for the development of the urinary catheter. Expert Rev Med Devices (2007) 0.84
Protein expression profiling during chick retinal maturation: a proteomics-based approach. Proteome Sci (2008) 0.84